The potential of lasmiditan in migraine

Lasmiditan, a highly selective 5-hydroxytryptamine receptor 1F (5-HT(1F)) agonist, is the first drug in its class and is lacking triptan-like vasoactive properties. The US Food and Drug Administration (FDA) has recently approved lasmiditan for the acute treatment of migraine in adults based on posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mecklenburg, Jasper, Raffaelli, Bianca, Neeb, Lars, Sanchez del Rio, Margarita, Reuter, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739205/
https://www.ncbi.nlm.nih.gov/pubmed/33403005
http://dx.doi.org/10.1177/1756286420967847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739205/
https://www.ncbi.nlm.nih.gov/pubmed/33403005
http://dx.doi.org/10.1177/1756286420967847

Ejemplares similares